Cutaneous Oncology News

Pembrolizumab monotherapy appeared to be effective and safe as first-line treatment for patients with unresectable cutaneous squamous cell carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.

The 31-gene expression profile test demonstrated consistent sensitivity in identifying patients with melanoma at risk for recurrence or distant metastasis, according to a study.

The prevalence of indoor tanning decreased in high school students following age restrictions on the practice in New Jersey, according to a study.

The combination of mogamulizumab and topical steroids conferred favorable outcomes to patients with previously treated cutaneous T-cell lymphoma, according to study results presented at Society of Hematologic Oncology Annual Meeting.

Two gene expression profile tests for cutaneous melanoma often failed to accurately identify recurrent stage I disease, according to a study.

Among a large cohort of patients with atopic dermatitis, treatment with topical calcineurin inhibitors demonstrated no association with elevated risk for keratinocyte carcinoma, according to a study.

Mutational heterogeneity was observed in almost 20% of melanoma tumors, according to a study.

A randomized phase 3 trial designed to evaluate the addition of spartalizumab to two targeted agents for the treatment of certain patients with advanced melanoma failed to meet its primary endpoint, according to the agent’s manufacturer.

A label change for the diuretic hydrochlorothiazide has been approved to include a small risk for non-melanoma skin cancer, the FDA announced in a press release.

Nivolumab plus ipilimumab- and pembrolizumab-based therapies may be the most cost-effective approaches in advanced melanoma, according to a study.